A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa

Trial Profile

A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs MEDI 3902 (Primary)
  • Indications Nosocomial pneumonia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms EVADE
  • Sponsors MedImmune
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 22 Feb 2019 to 19 Feb 2021.
    • 22 Jun 2017 Planned primary completion date changed from 22 Feb 2019 to 19 Feb 2021.
    • 11 Apr 2017 The study has been Discontinued in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top